Ensysce Biosciences, Inc. (NASDAQ:ENSC) Short Interest Update

Ensysce Biosciences, Inc. (NASDAQ:ENSC) was the target of a significant decrease in short interest in November. As of November 30th, there was short interest totalling 115,300 shares, a decrease of 97.6% from the November 15th total of 4,850,000 shares. Based on an average daily trading volume, of 1,760,000 shares, the days-to-cover ratio is presently 0.1 days.

Hedge Funds Weigh In On Ensysce Biosciences

An institutional investor recently bought a new position in Ensysce Biosciences stock. Anson Funds Management LP purchased a new stake in shares of Ensysce Biosciences, Inc. (NASDAQ:ENSC) during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 983,518 shares of the company’s stock, valued at approximately $236,000. Anson Funds Management LP owned 11.15% of Ensysce Biosciences as of its most recent SEC filing. Hedge funds and other institutional investors own 5.63% of the company’s stock.

Ensysce Biosciences Stock Down 8.2 %

ENSC stock traded down $0.50 during trading on Friday, reaching $5.62. The stock had a trading volume of 133,770 shares, compared to its average volume of 534,941. The company has a market capitalization of $7.36 million, a price-to-earnings ratio of -0.20 and a beta of 0.60. The company’s 50 day moving average is $6.93 and its two-hundred day moving average is $6.66. Ensysce Biosciences has a one year low of $2.12 and a one year high of $30.90.

Ensysce Biosciences (NASDAQ:ENSC) last posted its quarterly earnings data on Tuesday, November 12th. The company reported $1.05 EPS for the quarter, beating the consensus estimate of ($4.50) by $5.55. Ensysce Biosciences had a negative return on equity of 292.81% and a negative net margin of 179.26%. The business had revenue of $3.42 million for the quarter, compared to the consensus estimate of $0.25 million. As a group, research analysts predict that Ensysce Biosciences will post -12.44 earnings per share for the current fiscal year.

Ensysce Biosciences Company Profile

Ensysce Biosciences, Inc, a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.